<DOC>
	<DOCNO>NCT00430066</DOCNO>
	<brief_summary>The purpose study determine activity Glivec 400 mg po daily , single agent , induce haematological response Polycythemia Vera . The patient ask additional bone marrow blood sample collect : sample use evaluate disease respond drug .</brief_summary>
	<brief_title>Effects Imatinib Mesylate Polycythemia Vera</brief_title>
	<detailed_description>Hematocrit &lt; 45 % men &lt; 42 % woman 1Â°evaluation within 6 month In case complete partial responsiveness , experimental treatment continue 12 month In case disease progression treatment failure , experimental drug withdrawn patient study</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis Polycythemia Vera require treatment either phlebotomy Hydroxyurea Age &gt; 18 year Signed write informed consent form Pregnancy breastfeed Creatinine &gt; 3 max NV Bilirubin &gt; 3 max NV AST/ALT &gt; 3 max NV Concomitant severe psychiatric disorder Concomitant neoplastic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>